Sofia Esteves, Stéphanie Oliveira, Sara Duarte-Silva, Daniela Cunha-Garcia, Andreia Teixeira-Castro, Patrícia Maciel
Spinocerebellar ataxias are dominantly inherited neurodegenerative disorders with no disease-modifying treatment. We previously identified the selective serotonin reuptake inhibitor citalopram as a safe and effective drug to be repurposed for Machado-Joseph disease. Pre-symptomatic treatment of transgenic (CMVMJD135) mice strikingly ameliorated mutant ataxin-3 (ATXN3) pathogenesis. Here, we asked whether citalopram treatment initiated at a post-symptomatic age would still show efficacy. We used a cohort of CMVMJD135 mice that shows increased phenotypic severity and faster disease progression (CMVMJD135hi) compared to the mice used in the first trial. Groups of hemizygous CMVMJD135hi mice were orally treated with citalopram. Behavior, protein analysis, and pathology assessment were performed blindly to treatment. Our results show that even when initiated after symptom onset, treatment of CMVMJD135hi mice with citalopram ameliorated motor coordination and balance, attenuating disease progression, albeit to a lesser extent than that seen with pre-symptomatic treatment initiation. There was no impact on ATXN3 aggregation, which contrasts with the robust reduction in ATXN3-positive inclusions observed in CMVMJD135 mice, when treated pre-symptomatically. Post-symptomatic treatment of CMVMJD135hi mice revealed, however, a limited neuroprotective effect by showing a tendency to repair cerebellar calbindin staining, and to increase the number of motor neurons and of NeuN-positive cells in certain brain regions. While supporting that early initiation of treatment with citalopram leads to a marked increase in efficacy, these results strengthen our previous observation that modulation of serotonergic signaling by citalopram is a promising therapeutic approach for Machado-Joseph disease even after symptom onset.
J Neurosci. 1999 Apr 15;19(8):3248-57
[PMID:
10191337]
Mamm Genome. 2000 Sep;11(9):725-8
[PMID:
10967129]
Lab Anim. 2002 Jan;36(1):20-42
[PMID:
11831737]
Hum Mol Genet. 2002 May 1;11(9):1075-94
[PMID:
11978767]
Psychopharmacol Bull. 2003 Winter;37(1):96-121
[PMID:
14561952]
Neurochem Int. 2005 Aug;47(3):190-5
[PMID:
15955598]
Neuropsychopharmacology. 2008 Jan;33(1):88-109
[PMID:
17851537]
Curr Opin Neurol. 2008 Apr;21(2):111-6
[PMID:
18317266]
Neurobiol Dis. 2008 Jun;30(3):312-22
[PMID:
18403212]
Nature. 2008 Oct 16;455(7215):894-902
[PMID:
18923511]
Nature. 1991 Nov 7;354(6348):66-70
[PMID:
1944572]
J Neuropsychiatry Clin Neurosci. 2010 Winter;22(1):8-18
[PMID:
20160205]
Mol Neurodegener. 2010 Mar 12;5:10
[PMID:
20226030]
Neurobiol Dis. 2010 Oct;40(1):163-76
[PMID:
20510362]
J Immunol. 2010 Jul 15;185(2):1230-7
[PMID:
20566832]
PLoS Biol. 2010 Jun 29;8(6):e1000412
[PMID:
20613859]
Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14968-73
[PMID:
21873225]
Exp Neurol. 2012 Apr;234(2):405-16
[PMID:
22281106]
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD006534
[PMID:
22786497]
Nat Med. 2012 Oct;18(10):1531-8
[PMID:
23023499]
Neuron. 2012 Oct 4;76(1):175-91
[PMID:
23040814]
Restor Dent Endod. 2013 Feb;38(1):52-4
[PMID:
23495371]
Neuroscience. 2013 Sep 17;248:201-12
[PMID:
23721821]
Neurotherapeutics. 2014 Apr;11(2):433-49
[PMID:
24477711]
Sci Transl Med. 2014 May 14;6(236):236re4
[PMID:
24828079]
Curr Opin Neurobiol. 2015 Aug;33:1-7
[PMID:
25553359]
Curr Biol. 2015 Jan 19;25(2):163-174
[PMID:
25557666]
World J Clin Cases. 2015 Aug 16;3(8):682-93
[PMID:
26301229]
Brain. 2015 Nov;138(Pt 11):3221-37
[PMID:
26373603]
Cell. 2016 Sep 8;166(6):1553-1563.e10
[PMID:
27610575]
Brain. 2016 Nov 1;139(11):2891-2908
[PMID:
27645800]
Mol Neurobiol. 2019 May;56(5):3690-3701
[PMID:
30187384]
Neurology. 1978 Jul;28(7):703-9
[PMID:
566869]
J Genet Hum. 1981 Sep;29(3):203-9
[PMID:
6950024]
Neurology. 1980 Mar;30(3):319-22
[PMID:
7189034]
Am J Hum Genet. 1995 Jul;57(1):54-61
[PMID:
7611296]
Nat Genet. 1994 Nov;8(3):221-8
[PMID:
7874163]
Adv Neurol. 1993;61:139-53
[PMID:
8421964]
Mamm Genome. 1997 Oct;8(10):711-3
[PMID:
9321461]
